Clinical Research | Washington Center for Bleeding Disorders

The WACBD is staffed by several internationally recognized researchers and conducts numerous clinical and translational studies. Many of these studies are enabled and enhanced by a strong collaborative relationship with the Research Institute at Bloodworks Northwest and the University of Washington.

Community Counts

Community Counts is a public health monitoring program funded by CDC’s Division of Blood Disorders. The purpose of this project is to gather and share information about common health issues, medical complications, and causes of death that affect people with bleeding disorders cared for in U.S. Hemophilia Treatment Centers (HTCs).

https://www.cdc.gov/ncbddd/hemophilia/communitycounts/about.html#:~:text=About%20Community%20Counts%201%20Community%20Counts%20Gathers%20Health,Program%20Structure%205%20Components%20of%20Community%20Counts.%20 VISIT THE SITE »

American Thrombosis and Hemostasis Network (ATHN) - Transcends

ATHN Transcends is a natural history cohort study focused on participants with congenital or acquired non-neoplastic blood disorders and connective tissue disorders with bleeding tendencies. ATHN Transcends provides clinical researchers with a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data to increase knowledge in these important areas of research.

https://athn.org/what-we-do/national-projects/athn-projects-and-research-studies.html VISIT THE SITE »

Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A

https://clinicaltrials.gov/ct2/show/NCT04131036?term=Kruse-Jarres VISIT THE SITE »

Von Willebrand Factor in Pregnancy (VIP) Study

https://clinicaltrials.gov/ct2/show/NCT04146376?term=Konkle VISIT THE SITE »

A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A (XTEND-1)

https://clinicaltrials.gov/ct2/show/NCT04161495 VISIT THE SITE »

Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants With Moderately Severe to Severe Hemophilia A(FVIII:C≤1%)

https://clinicaltrials.gov/ct2/show/NCT04370054?titles=Phase+3%2C+Open-Label%2C+Single-Arm+Study+to+Evaluate+the+Efficacy+and+Safety+of+PF-07055480+%28Recombinant+AAV2%2F6+Human+Factor+VIII+Gene+Therapy%29+in+Adult+Male+Participants+with+Moderately+Severe+to+Severe+Hemophilia+A&draw=2&rank=1 VISIT THE SITE »

Phase III, open-label, single-dose, multi-center multinational trial investigating a serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene (AAV5-hFIXco-Padua, AMT-061) administered to adult subjects with severe or moderately severe hemophilia B

https://clinicaltrials.gov/ct2/show/NCT03569891 VISIT THE SITE »

Emicizumab in Patients With Acquired Hemophilia A (AHAEmi)

https://clinicaltrials.gov/ct2/show/NCT05345197?term=NCT05345197&draw=2&rank=1 VISIT THE SITE »

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

https://clinicaltrials.gov/ct2/show/NCT03938792 VISIT THE SITE »